Pharvaris – Hereditary Angioedema

Berndt Modig, CEO, and Dr. Jochen Knolle, CSO, discuss Pharvaris, a clinical-stage company focused on developing oral therapies for hereditary angioedema (HAE) patients. Hereditary angioedema is a rare and potentially life-threatening genetic condition with incidence between 1 in 10,000 and 1 in 50,000 people. Current therapies are limited by invasive routes of drug administration (injection or infusion), inconvenient dosing regimens, or undesired side effects.

Mr. Modig is a co-founder of Pharvaris and has served as Chief Executive Officer since its inception. Prior to Pharvaris, Berndt served as Chief Financial Officer of Prosensa Holding N.V., a biopharmaceutical company focusing on novel RNA modulating treatments for rare diseases like Duchenne muscular dystrophy, from March 2010 through its IPO on the NASDAQ in 2013 until its acquisition by BioMarin Pharmaceutical Inc. in January 2015 for up to $840M. From October 2003 to November 2008, he was Chief Financial Officer at Jerini AG through its IPO on the Frankfurt exchange in 2005 and sale to Shire plc in 2008. Jerini developed and launched icatibant for the treatment of hereditary angioedema (HAE), now currently marketed by Shire plc under the FIRAZYR brand name. Before Jerini, he served as Chief Financial Officer at Surplex AG from 2001 to 2003 and as Finance Director Europe of U.S.-based Hayward Industrial Products Inc. from 1999 to 2001. In previous positions, Mr. Modig was a Partner in the Brussels-based private equity firm Agra Industria from 1994 to 1999 and a Senior Manager in the Financial Services Industry Group of Price Waterhouse LLP in New York from 1991 to 1994.sale to Shire plc in 2008. Jerini developed and launched icatibant for the treatment of hereditary angioedema (HAE), now currently marketed by Shire plc under the FIRAZYR brand name. Before Jerini, he served as Chief Financial Officer at Surplex AG from 2001 to 2003 and as Finance Director Europe of U.S.-based Hayward Industrial Products Inc. from 1999 to 2001. In previous positions, Mr. Modig was a Partner in the Bruss Berndt also serves as a director and member of the audit committee of Axovant Sciences Ltd. and Affimed N.V., and as vice chairman and chair of the Audit Committee of Kiadis Pharma N.V. all publicly held pharmaceutical companies, and as member of the supervisory board of Centogene AG. Berndt received a bachelor’s degree in business administration, economics, and German from the University of Lund, Sweden, and an MBA from INSEAD, Fontainebleau, France. He is a certified public accountant (inactive).

Liked it? Take a second to support Nichol Macaraeg on Patreon!

0 Comments

Leave a Reply

You must be logged in to post a comment.